Tags

Type your tag names separated by a space and hit enter

Chromium picolinate reduces insulin resistance in polycystic ovary syndrome: Randomized controlled trial.

Abstract

AIM

To investigate the effect of chromium picolinate (CrP) on insulin resistance (IR) in polycystic ovary syndrome (PCOS).

METHODS

This double blinded randomized controlled trial was conducted in the Gynecology outpatient clinics at Ain Shams University Women's Hospital. Using closed and randomly mixed envelopes, 100 women were selected out of 400 PCOS patients. Eighty-five patients finished the study and were analyzed, 44 in group I and 41 in group II. They were randomly allocated to 6 months of either 1000 μg CrP (50 patients), or placebo capsules (50 patients). Patients were seen monthly to encourage similar diet control and physical exercise plans. The primary outcome was fasting glucose insulin ratio (FGIR), secondary outcomes included ovulation, regularity of the cycle, body mass index (BMI), fasting blood sugar (FBS), fasting serum insulin (FSI), and serum testosterone level.

RESULTS

There were no significant differences between women of both groups regarding pretreatment levels of FBS, FSI, FGIR, and serum testosterone. Use of CrP for 6 months was associated with significant reduction of BMI (P < 0.001) and FSI (P = 0.007), and significant rise in FGIR (P = 0.045). CrP significantly increased the chances of ovulation (P = 0.011) and regular menstruation (P = 0.002) by almost twofold after the fifth month of treatment.

CONCLUSION

Chromium picolinate is useful in PCOS to reduce IR and stimulate ovulation.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

    ,

    Department of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

    ,

    Department of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

    Department of Obstetrics and Gynecology, El-Sahel Hospital, Cairo, Egypt.

    Source

    MeSH

    Adult
    Dietary Supplements
    Female
    Humans
    Insulin Resistance
    Outcome Assessment (Health Care)
    Picolinic Acids
    Polycystic Ovary Syndrome
    Young Adult

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    26663540

    Citation

    Ashoush, Sherif, et al. "Chromium Picolinate Reduces Insulin Resistance in Polycystic Ovary Syndrome: Randomized Controlled Trial." The Journal of Obstetrics and Gynaecology Research, vol. 42, no. 3, 2016, pp. 279-85.
    Ashoush S, Abou-Gamrah A, Bayoumy H, et al. Chromium picolinate reduces insulin resistance in polycystic ovary syndrome: Randomized controlled trial. J Obstet Gynaecol Res. 2016;42(3):279-85.
    Ashoush, S., Abou-Gamrah, A., Bayoumy, H., & Othman, N. (2016). Chromium picolinate reduces insulin resistance in polycystic ovary syndrome: Randomized controlled trial. The Journal of Obstetrics and Gynaecology Research, 42(3), pp. 279-85. doi:10.1111/jog.12907.
    Ashoush S, et al. Chromium Picolinate Reduces Insulin Resistance in Polycystic Ovary Syndrome: Randomized Controlled Trial. J Obstet Gynaecol Res. 2016;42(3):279-85. PubMed PMID: 26663540.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Chromium picolinate reduces insulin resistance in polycystic ovary syndrome: Randomized controlled trial. AU - Ashoush,Sherif, AU - Abou-Gamrah,Amgad, AU - Bayoumy,Hassan, AU - Othman,Noura, Y1 - 2015/12/14/ PY - 2015/06/26/received PY - 2015/09/22/revised PY - 2015/10/18/accepted PY - 2015/12/15/entrez PY - 2015/12/15/pubmed PY - 2017/2/14/medline KW - chromium picolinate KW - infertility KW - insulin resistance KW - ovulation KW - polycystic ovary SP - 279 EP - 85 JF - The journal of obstetrics and gynaecology research JO - J. Obstet. Gynaecol. Res. VL - 42 IS - 3 N2 - AIM: To investigate the effect of chromium picolinate (CrP) on insulin resistance (IR) in polycystic ovary syndrome (PCOS). METHODS: This double blinded randomized controlled trial was conducted in the Gynecology outpatient clinics at Ain Shams University Women's Hospital. Using closed and randomly mixed envelopes, 100 women were selected out of 400 PCOS patients. Eighty-five patients finished the study and were analyzed, 44 in group I and 41 in group II. They were randomly allocated to 6 months of either 1000 μg CrP (50 patients), or placebo capsules (50 patients). Patients were seen monthly to encourage similar diet control and physical exercise plans. The primary outcome was fasting glucose insulin ratio (FGIR), secondary outcomes included ovulation, regularity of the cycle, body mass index (BMI), fasting blood sugar (FBS), fasting serum insulin (FSI), and serum testosterone level. RESULTS: There were no significant differences between women of both groups regarding pretreatment levels of FBS, FSI, FGIR, and serum testosterone. Use of CrP for 6 months was associated with significant reduction of BMI (P < 0.001) and FSI (P = 0.007), and significant rise in FGIR (P = 0.045). CrP significantly increased the chances of ovulation (P = 0.011) and regular menstruation (P = 0.002) by almost twofold after the fifth month of treatment. CONCLUSION: Chromium picolinate is useful in PCOS to reduce IR and stimulate ovulation. SN - 1447-0756 UR - https://www.unboundmedicine.com/medline/citation/26663540/full_citation L2 - https://doi.org/10.1111/jog.12907 DB - PRIME DP - Unbound Medicine ER -